By Aleesia Forni
Virginia Beach, March 4 - Gilead Sciences Inc. priced $4 billion of senior notes (Baa1/A-/) in three tranches, according to a company press release.
The sale included $500 million of 2.05% notes due April 2019 and $1.75 billion of 3.7% 10-year bonds.
There was also a $1.75 billion tranche of 4.8% bonds due 2044.
Full details of the sale were not available at press time.
BofA Merrill Lynch, J.P. Morgan Securities LLC, Goldman Sachs & Co. and Wells Fargo Securities LLC are the joint bookrunners.
Proceeds will be used for general corporate purposes.
The biopharmaceutical company is based in Foster City, Calif.
| Issuer: | Gilead Sciences Inc.
|
| Issue: | Senior notes
|
| Amount: | $4 billion
|
| Joint bookrunners: | BofA Merrill Lynch, J.P. Morgan Securities LLC, Goldman Sachs & Co., Wells Fargo Securities LLC
|
| Trade date: | March 4
|
| Settlement date: | March 7
|
| Ratings: | Moody's: Baa1
|
| Standard & Poor's: A-
|
|
|
| Notes due 2019
|
| Amount: | $500 million
|
| Maturity: | April 2019
|
| Coupon: | 2.05%
|
|
|
| Notes due 2024
|
| Amount: | $1.75 billion
|
| Maturity: | April 2024
|
| Coupon: | 3.7%
|
|
|
| Notes due 2044
|
| Amount: | $1.75 billion
|
| Maturity: | April 2044
|
| Coupon: | 4.8%
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
